AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

Sep. 30 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
26-09-28	€0.6940	+0.87%
26-09-25	€0.6880	-1.99%
26-09-24	€0.7020	-1.40%
26-09-23	€0.7120	-0.14%
26-09-22	€0.7130	-0.56%

Real-time Boerse Muenchen

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Boerse Muenchen 04:43:47 2026-09-28 pm EDT			5-day change	1st Jan Change
0.6940 ^EUR	+0.87%		-3.51%	-50.50%

Sep. 10	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
Aug. 17	AB Science completes settlement and delivery of its private placement

Market Cap	55.21M 62.77M 52.21M 47.35M 88.93M 6.03B 89.45M 625M 241M 3.07B 236M 231M 9.88B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	55.21M 62.77M 52.21M 47.35M 88.93M 6.03B 89.45M 625M 241M 3.07B 236M 231M 9.88B	EV / Sales 2026 *	46x	EV / Sales 2027 *	42.5x
Free-Float	69.03%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	AB	Real-time
CBOE	ABp	Real-time
London S.E.	0Q77	Delayed
Tradegate	A8D	Real-time
Boerse Muenchen	A8D	Real-time
Deutsche Boerse AG	A8D	Delayed
CBOE	0Q77	Real-time
Börse Stuttgart	A8D	Delayed

Sep. 10	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
Aug. 17	AB Science completes settlement and delivery of its private placement
Aug. 10	AB Science Wraps Up EUR14 Million Private Placements	MT
Aug. 10	AB Science raises €14.2m
Jul. 13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
Jul. 10	AB Science streamlines its portfolio and refocuses on two molecules
Jul. 10	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
Jul. 08	Stéphane Ledermann takes the helm at AB Science as CEO
Jul. 06	AB Science S.A. Announces Board Changes	CI
Jul. 06	AB Science S.A. Announces CEO Changes	CI
Jul. 02	AB Science S.A. announced that it has received $2.01616 million in funding	CI
Jul. 01	AB Science, successful private placement
Jun. 30	AB Science S.A. announced that it has received ?2.294 million in funding	CI

AB Science Stock Boerse Muenchen

Stocks

A8D

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news: AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Price Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

Aug. 17	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
Aug. 10	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL
Aug. 04	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
Jul. 10	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
Jul. 08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU

Sep. 28	Agenda Zonebourse des résultats de sociétés : semaine du 28 septembre au 2 octobre 2026
Sep. 25	Agenda Zonebourse des résultats de sociétés : semaine du 28 septembre au 2 octobre 2026
Aug. 24	AB Science : Franchissement de seuils et déclaration d'intention
Aug. 17	Bourse : Stellantis s'agite, ArgenX communique et PayPal fait monter les enchères
Aug. 17	AB Science procède au règlement-livraison de son placement privé

1 week	-3.21%
Current month	-0.43%
1 month	-4.28%
3 months	-19.95%
6 months	-39.97%
Current year	-50.07%

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	2026-07-06
Laurent Guy DFI	Director of Finance/CFO	-	2009-11-19
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	2018-03-31

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	2001-07-10
Stéphane Ledermann CHM	Chairman	-	2026-07-06
Patrick Moussy BRD	Director/Board Member	-	2011-09-19

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+0.87%	-3.51%	-44.66%	-68.95%	62.37M
MERCK & CO., INC.	-0.06%	-0.54%	+89.27%	+42.56%	367B
MERCK KGAA	+2.56%	+4.41%	+29.88%	-11.16%	66.89B
HALOZYME THERAPEUTICS, INC.	-0.89%	+1.29%	+53.07%	+188.35%	12.93B
KYOWA KIRIN CO., LTD.	+0.31%	-0.38%	-1.25%	-13.48%	7.54B
SK BIOPHARMACEUTICALS CO., LTD.	+0.40%	-1.80%	-24.93%	-11.60%	4.38B
YUHAN CORPORATION	+0.81%	-1.19%	-34.87%	+3.48%	4.07B
BETTA PHARMACEUTICALS CO., LTD.	-1.08%	-3.44%	-29.63%	-16.71%	3.02B
SUPERNUS PHARMACEUTICALS, INC.	+4.55%	+4.25%	-5.17%	+58.83%	2.48B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.84%	-4.15%	-21.36%	-32.38%	1.91B
Average	+0.77%	+0.07%	+1.04%	+13.89%	52.25B
Weighted average by Cap.	+1.26%	+1.64%	+74.51%	+36.57%

	2026 *	2027 *
Net sales	1.2M 1.36M 1.13M 1.03M 1.93M 131M 1.94M 13.59M 5.25M 66.83M 5.12M 5.01M 215M	1.3M 1.48M 1.23M 1.11M 2.09M 142M 2.11M 14.72M 5.68M 72.4M 5.55M 5.43M 233M
Net income	-	-
Net Debt	-	-

1 week	0.67	0.72
1 month	0.67	0.75
3 years	0.51	4.4
5 years	0.51	13.56